Wednesday, July 8, 2026

biotech · Recurrent Pericarditis · Acute Myocarditis · CRDL

Cardiol Therapeutics

Cardiol Therapeutics is a biotech organization headquartered in Toronto, CA. It trades on NYSE under ticker CRDL. Primary therapeutic focus areas include Recurrent Pericarditis, Acute Myocarditis, Spontaneous Coronary Ar

2265 Upper Middle Rd E, Suite 602, Greater Toronto Area, Ontario L6H 0G5, CA HQ
2017 Founded
27 Employees
Public company Type
CRDL · NYSE Ticker
Company details
Status
Public
HQ
2265 Upper Middle Rd E, Suite 602, Greater Toronto Area, Ontario L6H 0G5, CA
Founded
2017
Employees
27
Programs
11
Drugs
31
Patents
15
Clinical program

CardiolRx

Phase 3 · small molecule · Recurrent Pericarditis

CardiolRx for Recurrent Pericarditis is a Phase 3 program (small_molecule) at Cardiol Therapeutics with 2 ClinicalTrials.gov record(s).

← All Cardiol Therapeutics projects Phase 3 small molecule active

Internal code Cardiol 100-006

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Cardiol Therapeutics
Phase
Phase 3
Modality
small_molecule
Indication
Recurrent Pericarditis
Status
active
Trials
2

Clinical trials